Prosecution Insights
Last updated: September 17, 2026
Application No. 18/868,595

FILM-FORMING COLOR COSMETIC COMPOSITIONS

Non-Final OA §103
Filed
Nov 22, 2024
Priority
Jul 14, 2022 — provisional 63/368,385 +1 more
Examiner
HOLLOMAN, NANNETTE
Art Unit
Tech Center
Assignee
Revlon Consumer Products LLC
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
478 granted / 790 resolved
+0.5% vs TC avg
Strong +23% interview lift
Without
With
+23.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
27 currently pending
Career history
816
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
55.8%
+15.8% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
18.8%
-21.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 790 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-19 are rejected under 35 U.S.C. 103 as being unpatentable over Cheng et al. (US Patent Pub. 2010/0233301). Cheng et al. disclose cosmetic compositions in the form of lipstick and lip gloss ([0034]). Cheng et al. disclose the composition comprises about 0.1 to 50% oils (a), including polybutene or polyisobutene ([0036] and [0038]); emulsifiers including PEG-10 dimethicone at a concentration from about 0.01-40% (b); about 0.1 to 45% (c) film formers including trimethylsiloxysilicate ([0041]); and silicone elastomers structuring agents, including vinyl dimethicone/methicone silsesquioxane at a concentration of about 1-60% (d) ([0043] and [0046]). Cheng et al. disclose the compositions are applied to the skin ([0041]). The prior art discloses the use of 0.1 to 50% (a), 0.01-40% (b), 0.1 to 45% (c) and 2-60% (d). Thus, the prior art differs from the instant claims insofar as it does not disclose the particular endpoints recited therein, i.e. (a) 0.05 to 3%, (b) 0.05 to 3%, (c) 1 to 20% and (d) 0.5 to 5%. It is well-settled, however, that even a slight overlap in range establishes a prima facie case of obviousness. In re Peterson, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003). Accordingly, since an overlap plainly exists here, it would have been obvious to have selected values within the overlap, consistent with the reasoning of the Peterson decision. The prior discloses compositions containing at least one polyene, at least one polyether-modified silicone; at least one siloxysilicate rein; and at least one non-emulsifying silicone elastomer. Together these would provide a composition as claimed instantly. The prior art is not anticipatory insofar as these combinations must be selected from various lists/locations in the reference. It would have been obvious, however, to make the combination since each component is taught as being useful in making the compositions of the prior art. Since this modification of the prior art represents nothing more than “the predictable use of prior art elements according to their established functions” a prima facie case of obviousness exists. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANNETTE HOLLOMAN whose telephone number is (571)270-5231. The examiner can normally be reached Monday-Friday 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NANNETTE HOLLOMAN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Nov 22, 2024
Application Filed
Sep 02, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734181
METHODS FOR PREPARING LIPOSOMAL FORMULATIONS
2y 8m to grant Granted Sep 15, 2026
Patent 12728079
POWDER DISPERSION COMPOSITION AND COSMETIC OBTAINED USING SAME
3y 2m to grant Granted Sep 08, 2026
Patent 12716073
COMPOSITION OF SHELF-STABLE PLASMID DNA/POLYETHYLENEIMINE (PEI) PARTICLES WITH DEFINED SIZES FOR VIRAL VECTOR PRODUCTION AND METHOD FOR PREPARATION OF THE SAME
3y 0m to grant Granted Aug 25, 2026
Patent 12702648
TELODENDRIMER NANOCARRIERS FOR MONOMERIC AMPHOTERICIN B DELIVERY
2y 6m to grant Granted Aug 11, 2026
Patent 12691065
LIPOSOME FORMULATIONS FOR TREATMENT OF CANCERS AND DRUG RESISTANCE OF CANCERS
3y 8m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
84%
With Interview (+23.1%)
3y 0m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 790 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month